Company Profile
Kymera Therapeutics
Company Overview
Inventing New Possibilities, Transforming Treatment Paradigms
Kymera Therapeutics is a clinical stage biopharmaceutical company pioneering a transformative new modality, “targeted protein degradation” (TPD), with the ability to pursue targets long considered undruggable and to treat disease in entirely new ways. Its mission is to discover, develop and commercialize novel and transformative therapies to improve the lives of patients with serious diseases. Our team has developed a proprietary drug discovery engine, Pegasus, to enable the design of highly selective, small molecule protein degraders with potent activity against a broad range of disease indications. We are committed to selecting targets with the broadest possible impact across multiple disease indications with high unmet medical need to realize the full potential of TPD.
Kymera is led by an expert team of dedicated scientists and drug hunters, with decades of experience in the foundational areas of targeted protein degradation and drug development.
Company History
Founded in 2016 by current CEO Nello Mainolfi
Notable Accomplishments / Recognition
Kymera is working at the forefront of a new and exciting unique modality called targeted protein degradation (TPD) to invent new medicines for diseases with limited or no known treatment options, which is capable of targeting proteins traditionally undrugged by small molecules. TPD is a new powerful therapeutic modality which harnesses the body’s natural cellular recycling machinery – the ubiquitin proteasome system (UPS) – to break down or degrade unwanted proteins. The UPS comprises a series of finely orchestrated sequences involving critical enzymes called E3 ubiquitin ligases (E3 ligases) which direct the “tagging” of unwanted proteins with a molecule called ubiquitin. Importantly, we can chemically co-opt this innate cellular process using novel heterobifunctional molecules to direct the UPS toward specific disease-causing proteins. Specifically, TPD can target proteins without a catalytic function such as scaffolding proteins and transcription factors using small molecule-like drugs that can potentially be dosed orally and distributed systemically, unlike oligo-based therapeutics like RNAis.
Kymera is leveraging its knowledge and pre-clinical data packages to rapidly advance multiple drug candidates to the clinic – promising new therapies designed to treat serious immune inflammatory diseases and cancers with limited or no known treatment options. We focus on high impact targets, identifying clinically validated biological pathways with key nodes or proteins that drive the pathogenesis of multiple serious diseases, but have been elusive to conventional modalities. Our initial programs target IRAK4, IRAKIMiD, and STAT3, each of which center on a single critical signaling node within the IL-1R/TLR or JAK/STAT pathways. By degrading these targets, we have the potential to treat a broad range of immune-inflammatory diseases, hematologic malignancies, and solid tumors.
Benefits
BCBS HMO or PPO
Dependent Care
Fidelity 401k
Free garage parking
Free shuttle from Harvard Square to Arsenal Yards
Public Transportation Benefit
Health Savings Account
Vision Coverage
Life Insurance
Dependent Care
Unlimited vacation time
Paid Company Holidays – Winter shutdown
6 weeks of paid parental leave